Bone health history in breast cancer patients on aromatase inhibitors

Marilyn L. Kwan, Joan C. Lo, Li Tang, Cecile A. Laurent, Janise M. Roh, Malini Chandra, Theresa E. Hahn, Chi Chen Hong, Lara Sucheston-Campbell, Dawn L. Hershman, Charles P. Quesenberry, Christine B. Ambrosone, Lawrence H. Kushi, Song Yao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p,0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures.

Original languageEnglish (US)
Article numbere111477
JournalPLoS One
Volume9
Issue number10
DOIs
StatePublished - Oct 29 2014
Externally publishedYes

Fingerprint

Aromatase Inhibitors
breast neoplasms
Bone
bones
Health
Breast Neoplasms
Bone and Bones
history
osteoporosis
lifestyle
Life Style
Osteoporosis
demographic statistics
Demography
therapeutics
risk factors
aromatase
Postmenopausal Osteoporosis
cohort studies
cross-sectional studies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Kwan, M. L., Lo, J. C., Tang, L., Laurent, C. A., Roh, J. M., Chandra, M., ... Yao, S. (2014). Bone health history in breast cancer patients on aromatase inhibitors. PLoS One, 9(10), [e111477]. https://doi.org/10.1371/journal.pone.0111477

Bone health history in breast cancer patients on aromatase inhibitors. / Kwan, Marilyn L.; Lo, Joan C.; Tang, Li; Laurent, Cecile A.; Roh, Janise M.; Chandra, Malini; Hahn, Theresa E.; Hong, Chi Chen; Sucheston-Campbell, Lara; Hershman, Dawn L.; Quesenberry, Charles P.; Ambrosone, Christine B.; Kushi, Lawrence H.; Yao, Song.

In: PLoS One, Vol. 9, No. 10, e111477, 29.10.2014.

Research output: Contribution to journalArticle

Kwan, ML, Lo, JC, Tang, L, Laurent, CA, Roh, JM, Chandra, M, Hahn, TE, Hong, CC, Sucheston-Campbell, L, Hershman, DL, Quesenberry, CP, Ambrosone, CB, Kushi, LH & Yao, S 2014, 'Bone health history in breast cancer patients on aromatase inhibitors', PLoS One, vol. 9, no. 10, e111477. https://doi.org/10.1371/journal.pone.0111477
Kwan ML, Lo JC, Tang L, Laurent CA, Roh JM, Chandra M et al. Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014 Oct 29;9(10). e111477. https://doi.org/10.1371/journal.pone.0111477
Kwan, Marilyn L. ; Lo, Joan C. ; Tang, Li ; Laurent, Cecile A. ; Roh, Janise M. ; Chandra, Malini ; Hahn, Theresa E. ; Hong, Chi Chen ; Sucheston-Campbell, Lara ; Hershman, Dawn L. ; Quesenberry, Charles P. ; Ambrosone, Christine B. ; Kushi, Lawrence H. ; Yao, Song. / Bone health history in breast cancer patients on aromatase inhibitors. In: PLoS One. 2014 ; Vol. 9, No. 10.
@article{85501204315e445fbcdc6d8d4e51c3bd,
title = "Bone health history in breast cancer patients on aromatase inhibitors",
abstract = "A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2{\%} had a prior history of osteoporosis, 16.3{\%} had a prior history of any fracture, and 4.6{\%} had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5{\%} vs. 11.8{\%}, p,0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures.",
author = "Kwan, {Marilyn L.} and Lo, {Joan C.} and Li Tang and Laurent, {Cecile A.} and Roh, {Janise M.} and Malini Chandra and Hahn, {Theresa E.} and Hong, {Chi Chen} and Lara Sucheston-Campbell and Hershman, {Dawn L.} and Quesenberry, {Charles P.} and Ambrosone, {Christine B.} and Kushi, {Lawrence H.} and Song Yao",
year = "2014",
month = "10",
day = "29",
doi = "10.1371/journal.pone.0111477",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Bone health history in breast cancer patients on aromatase inhibitors

AU - Kwan, Marilyn L.

AU - Lo, Joan C.

AU - Tang, Li

AU - Laurent, Cecile A.

AU - Roh, Janise M.

AU - Chandra, Malini

AU - Hahn, Theresa E.

AU - Hong, Chi Chen

AU - Sucheston-Campbell, Lara

AU - Hershman, Dawn L.

AU - Quesenberry, Charles P.

AU - Ambrosone, Christine B.

AU - Kushi, Lawrence H.

AU - Yao, Song

PY - 2014/10/29

Y1 - 2014/10/29

N2 - A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p,0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures.

AB - A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p,0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures.

UR - http://www.scopus.com/inward/record.url?scp=84908610919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908610919&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0111477

DO - 10.1371/journal.pone.0111477

M3 - Article

C2 - 25354083

AN - SCOPUS:84908610919

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e111477

ER -